Unicycive Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Warrant Liability (Details) - USD ($) $ in Millions		9 Months Ended	12 Months Ended
Warrant Liability (Details) - USD ($) $ in Millions	Mar. 03, 2023	Sep. 30, 2024	Dec. 31, 2023	Jul. 11, 2023
Warrant Liability [Line Items]
Fair value of warrants	$ 2.8	$ 6.4	$ 13.1
Tranche A Warrant [Member] \| Series A-3 Preferred Stock [Member]
Warrant Liability [Line Items]
Acquired warrant shares	46,675,940			47,852,430
Tranche B Warrant [Member] \| Series A-4 Preferred Stock [Member]
Warrant Liability [Line Items]
Acquired warrant shares	42,432,672			43,502,206
Tranche C Warrant [Member] \| Series A-5 Preferred Stock [Member]
Warrant Liability [Line Items]
Acquired warrant shares	67,892,276			69,603,531